14 & 15 June 2023 Palexpo, Geneva

BIOCORP signs with HRA Pharma for the development of a medical device innovation

This agreement concerns the development and industrialization of an innovative medical device aiming to provide instant relief and faster healing of skin injuries.

After an initial concept and feasibility study conducted by BIOCORP, the two parties entered into an initial development agreement to design, test and validate a device in compliance with MDR (E.U. Medical Device Regulation) and FDA (U.S. Food and Drug Administration) requirements. BIOCORP will oversee the industrialization of this new device and the qualification of the manufacturing, filling, and packaging services within its plant in Issoire.

Follow us:

Share this article: